Skip to main content

Table 2 Malaria outcomes by treatment group

From: Effect of a single dose of oral azithromycin on malaria parasitaemia in children: a randomized controlled trial

  Azithromycin
N (%) or median (IQR)
Placebo
N (%) or median (IQR)
Odds ratio or mean difference (95% CI) P-value
Malaria parasitaemia
 14 days 44 (20.0%) 35 (17.0%) 1.22 (0.75 to 2.00) 0.43
 6 months 14 (7.6%) 10 (5.6%) 1.37 (0.59 to 3.16) 0.47
Parasite densitya
 14 days 188 (60 to 7087.5) 520 (120 to 5800) − 0.44 (− 1.60 to 0.71) 0.45
 6 months 108 (64 to 540) 256 (88 to 790) − 0.21 (− 1.55 to 1.12) 0.74
Gametocytaemia
 14 days 39 (17.7%) 31 (15.1%) 1.22 (0.73 to 2.04) 0.46
 6 months 14 (7.6%) 9 (5.1%) 1.53 (0.64 to 3.63) 0.34
Parasitaemia plus feverb
 14 days 7 (3.2%) 4 (1.9%) 1.66 (0.48 to 5.75) 0.43
 6 months 3 (1.6%) 1 (0.6%) 2.90 (0.30 to 28.2) 0.36
  1. IQR interquartile range CI confidence interval
  2. aAmong children with a positive smear, with models using a log transformation of parasite density
  3. bFever defined as tympanic temperature ≥ 37.5 °C